aTyr Pharma, Inc.
ATYR
$3.10
$0.082.65%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 235.00K | 235.00K | 588.00K | 588.00K | 353.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 235.00K | 235.00K | 588.00K | 588.00K | 353.00K |
| Cost of Revenue | 54.37M | 54.90M | 50.41M | 46.28M | 42.29M |
| Gross Profit | -54.14M | -54.66M | -49.82M | -45.69M | -41.94M |
| SG&A Expenses | 13.78M | 13.39M | 12.70M | 13.08M | 12.98M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 68.15M | 68.29M | 63.11M | 59.36M | 55.27M |
| Operating Income | -67.91M | -68.05M | -62.53M | -58.77M | -54.92M |
| Income Before Tax | -64.02M | -63.82M | -57.90M | -53.93M | -50.40M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -64.02 | -63.82 | -57.90 | -53.93 | -50.40 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -1.00K | -1.00K | -1.00K | 3.00K | 8.00K |
| Net Income | -64.02M | -63.82M | -57.90M | -53.93M | -50.39M |
| EBIT | -67.91M | -68.05M | -62.53M | -58.77M | -54.92M |
| EBITDA | -67.21M | -67.35M | -61.82M | -58.08M | -54.33M |
| EPS Basic | -0.87 | -0.94 | -0.91 | -0.90 | -0.95 |
| Normalized Basic EPS | -0.54 | -0.59 | -0.57 | -0.56 | -0.60 |
| EPS Diluted | -0.87 | -0.94 | -0.91 | -0.90 | -0.95 |
| Normalized Diluted EPS | -0.54 | -0.59 | -0.57 | -0.56 | -0.60 |
| Average Basic Shares Outstanding | 296.89M | 273.43M | 255.51M | 238.37M | 214.19M |
| Average Diluted Shares Outstanding | 296.89M | 273.43M | 255.51M | 238.37M | 214.19M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |